SCHEMBL5118435

SCHEMBL5118435

Cc1cnc(Cl)cc1C=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C19 P33261 1/20 0.42
ALDH1A1 P00352 7/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MEN1 O00255 2/20 0.40
MAPT P10636 2/20 0.40
KMT2A Q03164 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MPI P34949 1/20 0.40
GRIA1 P42261 1/20 0.37
GRIA2 P42262 1/20 0.37
GRIA3 P42263 1/20 0.37
GRIA4 P48058 1/20 0.37
TSHR P16473 1/20 0.35
ERN1 O75460 4/20 0.34
PTPN1 P18031 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
KCNJ1 P48048 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29878553 1.00 CYP1A2 (0.42) CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1
SCHEMBL7996324 0.83 CYP3A4 (0.42) CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1
SCHEMBL22980719 0.79 ALDH1A1 (0.35) ALDH1A1CHRNB2CHRNA4LMNANOS3
SCHEMBL29697292 0.79 ALDH1A1 (0.35) ALDH1A1CHRNB2CHRNA4LMNANOS3
SCHEMBL6627536 0.78 GRIA1 (0.44) CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1
SCHEMBL30589401 0.78 TDP1 (0.40) CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1
SCHEMBL1533918 0.78 TDP1 (0.40) CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1
SCHEMBL29952665 0.78 GRIA1 (0.44) CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1
SCHEMBL13909495 0.76
SCHEMBL24086660 0.75 GRIA1 (0.37) CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
WO-2019164778-A1 PROCESS FOR PREPARING 1-ARYLSULFONYL-PYRROLIDINE-2-CARBOXAMIDE TRANSIENT RECEPTOR POTENTIAL CHANNEL ANTAGONIST COMPOUNDS AND CRYSTALLINE FORMS THEREOF GENENTECH, INC. (US) 2019-08-29 WO disclosed
US-20080167314-A1 Condensed Imidazole Compound And Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
EP-1832588-A1 CONDENSED IMIDAZOLE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2007-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167314-A1 Condensed Imidazole Compound And Use Thereof MAPK13, MMP13, MAPK3 CYP1A2 2673/4885CYP3A4 2027/4885CYP2D6 3259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.